A 58-year-old man with chronic obstructive pulmonary disease (COPD) and recent oral corticosteroid use presents with a 3-week history of productive cough with hemoptysis, low-grade fever, and weight loss. High-resolution CT chest shows a cavitary lesion in the right upper lobe with a mobile opacity (fungal ball) inside the cavity. Sputum microscopy is negative for acid-fast bacilli. What is the most appropriate next step in management?

Explanation

## Chronic Pulmonary Aspergillosis (CPA) – Aspergilloma **Key Point:** The clinical and radiological presentation (cavitary lesion with fungal ball in a COPD patient on corticosteroids) is classic for aspergilloma. Diagnosis requires mycological confirmation (culture ± serology), and antifungal therapy should begin empirically while awaiting culture results. **High-Yield:** Aspergilloma is a chronic infection of pre-existing lung cavities (TB, sarcoidosis, COPD). Unlike acute invasive aspergillosis, it responds to prolonged oral azole therapy (itraconazole or voriconazole) in ~50% of cases. Surgery is reserved for treatment failures or life-threatening hemoptysis. ## Diagnostic and Management Algorithm for Aspergilloma ```mermaid flowchart TD A[Cavitary lesion + fungal ball<br/>on imaging]:::outcome --> B[Obtain sputum culture<br/>& Aspergillus serology]:::action B --> C{Clinical suspicion<br/>high?}:::decision C -->|Yes| D[Start itraconazole 200 mg BD<br/>empirically]:::action C -->|No| E[Await culture confirmation]:::action D --> F[Culture confirms<br/>Aspergillus fumigatus]:::outcome E --> F F --> G{Clinical response<br/>at 3 months?}:::decision G -->|Yes| H[Continue itraconazole<br/>6-12 months]:::action G -->|No| I[Switch to voriconazole<br/>or consider surgery]:::action I --> J{Recurrent hemoptysis<br/>or deterioration?}:::decision J -->|Yes| K[Surgical resection<br/>if feasible]:::urgent J -->|No| L[Continue medical therapy]:::action ``` ## Why Empirical Itraconazole While Awaiting Culture? | Reason | Explanation | |--------|-------------| | **Clinical diagnosis is clear** | Cavitary lesion + fungal ball + immunocompromised host (COPD + corticosteroids) = aspergilloma until proven otherwise. | | **Culture takes 2–4 weeks** | Delaying therapy by weeks is suboptimal. Empirical therapy is justified by high pre-test probability. | | **Itraconazole is first-line** | Oral azole therapy is standard for chronic pulmonary aspergillosis. Response rates are ~50% with prolonged therapy (6–12 months). | | **Serology supports diagnosis** | Aspergillus-specific IgG and precipitins are highly specific for aspergilloma and appear early. | | **Safety profile** | Itraconazole is well-tolerated for prolonged use; monitoring for drug interactions and hepatotoxicity is routine. | **Mnemonic:** **ASPERGILLOMA** = **A**ntifungal empirically, **S**putum culture & serology, **P**rolonged therapy (6–12 months), **E**valuate response at 3 months, **R**esection if medical failure, **G**alactomannan optional, **I**traconazole first-line, **L**obectomy for hemoptysis, **L**ow mortality with early treatment, **O**ral azoles preferred, **M**onitoring essential, **A**void delay. **Clinical Pearl:** Galactomannan antigen testing is more useful in acute invasive aspergillosis (immunocompromised patients with pneumonia) than in aspergilloma. In aspergilloma, sputum culture and serology are the diagnostic pillars. **Warning:** Do NOT wait for culture confirmation before starting itraconazole in a patient with classic aspergilloma presentation. The risk of progression (hemoptysis, dissemination) outweighs the benefit of diagnostic certainty.